

EE487: Exploring the Healthcare Resource Utilization (HCRU) Associated with Rare Diseases (RD) in the United States (US): A Systematic Literature Review (SLR) across Six Disease Areas

SLR references with data relating to HCRU

Huntington's disease

1. Claassen DO, DeCourcy J, Mellor J, Johnston C, Iyer RG. Impact of Chorea on Self-care Activity, Employment, and Health-care Resource Use in Patients with Huntington's Disease. *J Health Econ Outcomes Res.* 2021 Jun 21;8(1):99-105. doi: 10.36469/001c.24620. PMID: 34183975; PMCID: PMC8216765.
2. Exuzides A, Crowell V, Reddy S, Chang E, Yohrling G. (2020). Healthcare utilization and costs by disease stage in beneficiaries with Huntington's disease in the US Medicare population [abstract]. *Virtual ISPOR 2020*, May 18-20 2020. *Virtual ISPOR 2020*, May 18–20 2020.
3. Exuzides A, To TM, Abbass IM, Surinach A, Fuller R, Luo J. (2020). A US retrospective commercial claims analysis of healthcare utilization and costs of Huntington's disease by stage [abstract].
4. Exuzides A, To TM, Abbass IM, Ta J, Surinach A, Fuller R, Luo J. (2021). Healthcare resource utilization and costs among patients with versus without Huntington's disease in the US population [abstract]. *Academy of Managed Care Pharmacy 2021 Annual Meeting*, Virtual meeting; 12–16 April 2021.
5. Exuzides A, Reddy SR, Chang E, Ta JT, Patel AM, Paydar C, Yohrling GJ. Healthcare utilization and cost burden of Huntington's disease among Medicare beneficiaries in the United States. *J Med Econ.* 2021 Jan-Dec;24(1):1327-1336. doi: 10.1080/13696998.2021.2002579. PMID: 34730477.
6. Exuzides A, To TM, Abbass IM, Ta JT, Patel AM, Surinach A, Fuller RLM, Luo J. Healthcare resource utilization and costs in individuals with Huntington's disease by disease stage in a US population. *J Med Econ.* 2022 Jan-Dec;25(1):722-729. doi: 10.1080/13696998.2022.2076997. PMID: 35608039.
7. Hamedani AG, Pauly M, Thibault DP, Gonzalez-Alegre P, Willis AW. Inpatient gastrostomy in Huntington's disease: Nationwide analysis of utilization and outcomes compared to amyotrophic lateral sclerosis. *Clin Park Relat Disord.* 2020 Jan 24;3:100041. doi: 10.1016/j.prdoa.2020.100041. PMID: 34316627; PMCID: PMC8298766.
8. Johnson MO, Frank S, Mendlik M, Casarett D. Utilization of Hospice Services in a Population of Patients With Huntington's Disease. *J Pain Symptom Manage.* 2018 Feb;55(2):440-443. doi: 10.1016/j.jpainsymman.2017.09.004. Epub 2017 Sep 13. PMID: 28916295.
9. Parast L, Haas A, Teno J, Elliott M, Griffin BA, Price RA. Hospice Care Experiences Among Decedents With Huntington's Disease. *J Pain Symptom Manage.* 2022 Jul;64(1):70-79. doi: 10.1016/j.jpainsymman.2022.02.342. Epub 2022 Mar 6. PMID: 35263620; PMCID: PMC10859183.
10. Petrillo J, Koenig A, Sawant R, Zhang X, Hwang S. (2022). Healthcare resource use, concomitant conditions, and treatment patterns in Huntington's disease: A commercial claims analysis [abstract]. *Value in Health* 25(7):S423.

11. Reddy S, Exuzides A, Chang E, Ta J, Patel A, Paydar C, Yohrling G. (2021). Healthcare Utilization and Costs at End-of-Life Among US Medicaid Beneficiaries with Huntington's Disease [abstract]. *Value in Health* 24(5):S1
12. Reddy S, Exuzides A, Chang E, Ta J, Paydar C, Yohrling G. (2020). Healthcare utilization and cost burden at the end of life among Medicare beneficiaries with Huntington's disease [abstract]. 24th International Congress of Parkinson's Disease and Movement Disorders; 12-16 September 2020.
13. Reynolds EL, Gallagher G, Hill CE, Banerjee M, Mante A, Esper GJ, Callaghan BC. Costs and Utilization of New-to-Market Neurologic Medications. *Neurology*. 2023 Feb 28;100(9):e884-e898. doi: 10.1212/WNL.0000000000201627. Epub 2022 Nov 30. PMID: 36450601; PMCID: PMC9990429.
14. Sokol LL, Bega D, Yeh C, Kluger BM, Lum HD. Disparities in Palliative Care Utilization Among Hospitalized People With Huntington Disease: A National Cross-Sectional Study. *Am J Hosp Palliat Care*. 2022 May;39(5):516-522. doi: 10.1177/104990912111034419. Epub 2021 Jul 22. PMID: 34291654; PMCID: PMC9436638.
15. Ta J, To TM, Patel A, Ambass Im, Gandhi R. (2021). 251 Healthcare utilization in individuals with late onset versus adult-onset Huntington's disease [abstract]. *Mov Disord*. 2021; 36 (suppl 1).
16. Ta J, Reddy S, Patel A, Chang E, Exuzides E, Gandhi R, Yohrling G. (2021). Burden of illness among US Medicare beneficiaries with late-onset Huntington's disease [abstract]. Academy of Managed Care Pharmacy 2021 Annual Meeting, Virtual meeting; 12–16 April 2021.
17. To TM, Exuzides A, Abbass IM, Patel AM, Ta JT, Surinach A, Fuller RLM, Luo J. Health care resource utilization and costs among individuals with vs without Huntington disease in a US population. *J Manag Care Spec Pharm*. 2022 Nov;28(11):1228-1239. doi: 10.18553/jmcp.2022.28.11.1228. PMID: 36282937; PMCID: PMC10373050.

Dystrophic Epidermolysis Bullosa

1. Feinstein JA, Bruckner AL, Chastek B, Anderson A, Roman J. Clinical characteristics, healthcare use, and annual costs among patients with dystrophic epidermolysis bullosa. *Orphanet J Rare Dis*. 2022 Sep 29;17(1):367. doi: 10.1186/s13023-022-02509-0. PMID: 36175960; PMCID: PMC9524120.
2. Roman J, Chastek B. (2022). L16 Characteristics and burden of illness among patients diagnosed with dystrophic epidermolysis bullosa [abstract]. Academy of Managed Care Pharmacy 2022 Annual Meeting; March 29-April 1 2022.

Hereditary angioedema

1. Anderson J, Craig T, Mellor J, Earl L, Connolly H, Wynne-Cattanach K, Sing K, Juethner S, Schultz B. (2023). Comparison of Hereditary Angioedema Among Patients of Different Races and Ethnicities in the United States: Data From a Real-World Study [abstract]. *Journal of Allergy and Clinical Immunology* 151(2):AB137.
2. Banerji A, Davis KH, Brown TM, Hollis K, Hunter SM, Long J, Jain G, Devercelli G. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. *Ann Allergy Asthma Immunol*. 2020 Jun;124(6):600-607. doi: 10.1016/j.anai.2020.02.018. Epub 2020 Mar 10. PMID: 32169514.

3. Castaldo AJ, Jervelund C, Corcoran D, Boysen HB, Christiansen SC, Zuraw BL. Assessing the cost and quality-of-life impact of on-demand-only medications for adults with hereditary angioedema. *Allergy Asthma Proc.* 2021 Mar 13;42(2):108-117. doi: 10.2500/aap.2021.42.200127. Epub 2021 Feb 13. PMID: 33581742; PMCID: PMC8133018.
4. Cheng BT, Silverberg JI, Samet JD, Fishbein AB. Burden of emergency department utilization and abdominal imaging for hereditary angioedema. *J Allergy Clin Immunol Pract.* 2020 Apr;8(4):1443-1446.e2. doi: 10.1016/j.jaip.2019.10.028. Epub 2019 Nov 5. PMID: 31704443; PMCID: PMC7394264.
5. Juethner S, Moran K, Mellor J, Hatchell N, Earl L. (2022). RWD47 Understanding Patient Characteristics and Healthcare Resource Utilization in Patients With HAE Currently Prescribed Prophylactic Treatment [abstract]. *IPSOR 2022*; May 15-18, 2022.
6. Riedl M, Gower RG, Chrvala CA. Current medical management of hereditary angioedema: results from a large survey of US physicians. *Ann Allergy Asthma Immunol.* 2011 Apr;106(4):316-322.e4. doi: 10.1016/j.anai.2010.12.012. Epub 2011 Feb 5. PMID: 21457880.
7. Riedl MA, Banerji A, Manning ME, Burrell E, Joshi N, Patel D, Machnig T, Tai MH, Watson DJ. Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States. *Orphanet J Rare Dis.* 2018 Oct 12;13(1):180. doi: 10.1186/s13023-018-0922-3. PMID: 30314518; PMCID: PMC6186115.
8. Riedl MA, Hinds D, Alvord T, Dosenovic S, Abdelhadi J, Brownrigg J, Camp C, Banerji A. (2022). P058 Healthcare resource utilization among lanadelumab and subcutaneous c1-inhibitor concentrate new users - retrospective database study [abstract]. *Annals of Allergy, Asthma & Immunology*; 129(5):S28-S29.
9. Tachdjian R, Johnson KE, Casso D, Oliveria SA, Devercelli G, Jain G. Real-world cohort study of adult and pediatric patients treated for hereditary angioedema in the United States. *Allergy Asthma Proc.* 2020 May 1;41(3):172-182. doi: 10.2500/aap.2020.41.200011. Epub 2020 Mar 18. PMID: 32375961.
10. Tachdjian R, Soteres D, Anderson J, Mellor J, Connolly H, Wynne-Cattanach K, Earl L, Schultz B, Juethner S. (2023). Disease Burden and Physician-Reported Outcomes in Pediatric Patients With Hereditary Angioedema: Data From A Real World Study [abstract]. *The Journal of Allergy and Clinical Immunology*; 151(2):AB142.

Transthyretin amyloidosis

1. Aggarwal S, Bela A, Topaloglu O. (2020). ND2 burden of hospitalizations in hereditary transthyretin amyloidosis (hATTR) with and without hematopoietic stem cell transplant: a propensity score matched analysis of in-patient claims database [abstract]. *Value in Health*; 23(1):S9.
2. Ortiz Perez JT, Fine NM, Brown D, Vera Llonch M, Reddy S, Chang E, Tarbox MH, Nativi-Nicolau J. (2021). Cardiovascular symptom burden prior to diagnosis of transthyretin amyloidosis among medicare beneficiaries [abstract]. *Journal of the American College of Cardiology.* 2021 May, 77 (18_Supplement_1) 746.
3. Reddy SR, Chang E, Tarbox MH, Broder MS, Tieu RS, Guthrie S, Vera-Llonch M, Pollock MR. The Clinical and Economic Burden of Newly Diagnosed Hereditary Transthyretin (ATTRv) Amyloidosis: A Retrospective Analysis of Claims Data. *Neurol Ther.* 2020 Dec;9(2):473-482. doi: 10.1007/s40120-020-00194-4. Epub 2020 May 25. PMID: 32451849; PMCID: PMC7606386.

4. Rozenbaum MH, Tran D, Bhambri R, Nativi-Nicolau J. Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy. *Am J Cardiovasc Drugs*. 2022 Jul;22(4):445-450. doi: 10.1007/s40256-022-00526-9. Epub 2022 Mar 30. PMID: 35353352; PMCID: PMC9270297.
5. Rubens M, Saxena A, Ruiz Pelaez J, Chaparro S, Jimenez J. Adverse outcomes among hospitalizations for transthyretin amyloidosis related heart failure [abstract]. *Journal of the American College of Cardiology*. 2023 Mar, 81 (8_Supplement) 403.
6. Stewart M, Shaffer S, Murphy B, Loftus J, Alvir J, Cicchetti M, Lenderking WR. Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers. *Neurol Ther*. 2018 Dec;7(2):349-364. doi: 10.1007/s40120-018-0106-z. Epub 2018 Aug 2. PMID: 30073497; PMCID: PMC6283802.
7. Vaishnav J, Hubbard A, Chasler JE, Lepley D, Cuomo K, Riley S, Menzel K, Fajardo J, Sharma K, Judge DP, Russell SD, Gilotra NA. Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic. *Am Heart J*. 2021 Mar;233:122-131. doi: 10.1016/j.ahj.2020.12.009. Epub 2020 Dec 22. PMID: 33352187.
8. Vera-Llonch M, Reddy SR, Chang E, Tarbox MH, Pollock M. The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis. *Orphanet J Rare Dis*. 2021 Jan 11;16(1):25. doi: 10.1186/s13023-020-01623-1. PMID: 33430941; PMCID: PMC7798313.

Alpha-1 antitrypsin deficiency

1. Axley P, Ahmed Z, Arora S, Haas A, Kuo YF, Kamath PS, Singal AK. NASH Is the Most Rapidly Growing Etiology for Acute-on-Chronic Liver Failure-Related Hospitalization and Disease Burden in the United States: A Population-Based Study. *Liver Transpl*. 2019 May;25(5):695-705. doi: 10.1002/lt.25443. PMID: 30861321.
2. Campos MA, Runken MC, Davis AM, Johnson MP, Stone GA, Buikema AR. Impact of a Health Management Program on Healthcare Outcomes among Patients on Augmentation Therapy for Alpha 1-Antitrypsin Deficiency: An Insurance Claims Analysis. *Adv Ther*. 2018 Apr;35(4):467-481. doi: 10.1007/s12325-018-0690-4. Epub 2018 Apr 3. PMID: 29616482; PMCID: PMC5910458.
3. Choate R, Sandhaus RA, Holm KE, Mannino DM, Strange C. Patient-Reported Pulmonary Symptoms, Exacerbations, and Management in a Cohort of Patients With Alpha-1 Antitrypsin Deficiency. *Chronic Obstr Pulm Dis*. 2022 Oct 26;9(4):549-561. doi: 10.15326/jcopdf.2022.0317. PMID: 36103189; PMCID: PMC9718576.
4. Herrera EM, Joseph C, Brouwer ES, Gandhi V, Czorniak M. Alpha-1 Antitrypsin Deficiency-Associated Clinical Manifestations and Healthcare Resource Use in the United States. *COPD*. 2021 Jun;18(3):315-324. doi: 10.1080/15412555.2021.1917532. Epub 2021 May 26. PMID: 34036848.
5. Herrera EM, Joseph C, Bouwer ES. (2020). Analysis of pulmonary-related clinical manifestations and healthcare resource use in patients in the united states with alpha-1 antitrypsin deficiency [abstract]. *Chest*; 156(4):A424.
6. Lee D, Fan G, Karagozian R. (2020). S1039 The Clinical Outcomes of Hospitalized Patients With Alpha-1-Antitrypsin Deficiency-Related Cirrhosis [abstract]. *The American Journal of Gastroenterology*; 115(1):S528:S528.

7. Lee D, Fan G, Karagozian R. (2021). 657 The risk factors associated with hospital death in patients admitted with alpha-1 antitrypsin deficiency-related liver disease [abstract]. *Gastroenterology*; 160(6):S-791
8. Niu B, Kim B, Limketkai BN, Sun J, Li Z, Woreta T, Chen PH. Mortality from Spontaneous Bacterial Peritonitis Among Hospitalized Patients in the USA. *Dig Dis Sci*. 2018 May;63(5):1327-1333. doi: 10.1007/s10620-018-4990-y. Epub 2018 Feb 26. PMID: 29480417; PMCID: PMC5897146.
9. Olaso DG, Halpern SE, Krischak MK, Au S, Jamieson IR, Haney JC, Klapper JA, Hartwig MG. Same-teams versus different-teams for long distance lung procurement: A cost analysis. *J Thorac Cardiovasc Surg*. 2023 Mar;165(3):908-919.e3. doi: 10.1016/j.jtcvs.2022.05.040. Epub 2022 Jun 10. PMID: 35840431; PMCID: PMC9734279.
10. Rueda JD, Sieluk J, Sandhaus RA, Mullins CD. Limitations and Challenges of Conducting Budget Impact Analyses in Rare Diseases: A Case Study of Alpha-1 Antitrypsin Deficiency. *Value Health Reg Issues*. 2020 Dec;23:70-76. doi: 10.1016/j.vhri.2020.04.003. Epub 2020 Sep 3. PMID: 32892111.
11. Sieloff EM, Rutledge B, Huffman C, Vos D, Melgar T. National trends and outcomes of genetically inherited non-alcoholic chronic liver disease in the USA: estimates from the National Inpatient Sample (NIS) database. *Gastroenterol Rep (Oxf)*. 2021 Jan 15;9(1):38-48. doi: 10.1093/gastro/goaa091. PMID: 33747525; PMCID: PMC7962742.
12. Sieloff EM, Rutledge B, Huffman C, Vos D, Melgar T. (2020). Sa1554 national trends and outcomes of genetically inherited metabolic forms of liver cirrhosis: results from the national inpatient sample (NIS) database [abstract]. *Gastroenterology*, 158.
13. Sieluk J, Levy J, Sandhaus RA, Silverman H, Holm KE, Mullins CD. Costs of Medical Care Among Augmentation Therapy Users and Non-Users with Alpha-1 Antitrypsin Deficiency in the United States. *Chronic Obstr Pulm Dis*. 2019 Nov 8;6(1):6-16. doi: 10.15326/jcopdf.6.1.2017.0187. PMID: 30775420; PMCID: PMC6373584.
14. Sieluk J, Slejko JF, Silverman H, Perfetto E, Mullins CD. Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States. *Orphanet J Rare Dis*. 2020 Sep 23;15(1):260. doi: 10.1186/s13023-020-01523-4. PMID: 32967697; PMCID: PMC7510284.
15. Stone GA, Blanchette CM, Stranton D, Whitmire S, Oh J, Howden R. (2020). Healthcare cost and utilization before and after diagnosis of alpha-1 antitrypsin deficiency in the United States [abstract]. *American Journal of Respiratory and Critical Care Medicine* 2020;201:A6275.
16. Zou B, Yeo YH, Jeong D, Park H, Sheen E, Lee DH, Henry L, Garcia G, Ingelsson E, Cheung R, Nguyen MH. A Nationwide Study of Inpatient Admissions, Mortality, and Costs for Patients with Cirrhosis from 2005 to 2015 in the USA. *Dig Dis Sci*. 2020 May;65(5):1520-1528. doi: 10.1007/s10620-019-05869-z. Epub 2019 Oct 9. PMID: 31598919.

Stargardt disease

1. Aziz K, Swenor BK, Canner JK, Singh MS. The Direct Healthcare Cost of Stargardt Disease: A Claims-Based Analysis. *Ophthalmic Epidemiol*. 2021 Dec;28(6):533-539. doi: 10.1080/09286586.2021.1883675. Epub 2021 Feb 21. PMID: 33615979.